Organogenesis Holdings Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023. The unaudited filing covers a regenerative medicine company serving Advanced Wound Care and Surgical & Sports Medicine markets. Comparative figures are for Q1 2022 unless stated otherwise. Amounts below are in U.S. dollars.
Financial performance
| Metric | Q1 2023 | Q1 2022 | Change / context |
|---|---|---|---|
| Net revenue | $107.6 million | $97.1 million | Up 11% |
| Gross profit | $81.0 million | $72.0 million | Up 12% |
| Gross margin | 75% | 74% | Improved, partly from product mix |
| Operating expenses | $85.0 million | $72.2 million | Up 18% |
| Operating loss | $4.0 million | $0.1 million | Widened |
| Net loss | $3.0 million | $0.9 million | Loss per share: $0.02 vs. $0.01 |
| Adjusted EBITDA (non-GAAP) | $3.8 million | $5.0 million | Down 25% |
| Cash from operating activities | $(5.1) million | $1.4 million | Cash use increased |
| Capital expenditures | $7.6 million | $6.7 million | Investing cash outflow |
Advanced Wound Care revenue rose 12% to $100.9 million, primarily from increased sales to existing and new customers. Surgical & Sports Medicine revenue declined 4% to $6.7 million, primarily attributed to sales-force attrition. SG&A increased 16% to $73.8 million, reflecting the timing of the annual sales meeting, added headcount, legal and consulting costs, and restructuring. R&D increased 30% to $11.2 million, driven by pipeline product costs, clinical and regulatory work, and headcount.
Cash, debt and liquidity
- At March 31, 2023, cash and cash equivalents were $88.7 million; restricted cash was $0.7 million. Cash, cash equivalents and restricted cash declined $13.9 million during the quarter.
- Working capital was $140.7 million. Accounts receivable, net, was $92.0 million and inventory was $25.5 million.
- Term-loan borrowings were $70.3 million; no revolver borrowings were outstanding, with $125.0 million available. The term loan is secured by substantially all company assets, including intellectual property, and matures August 2026. The company reported covenant compliance.
- Operating lease liabilities totaled $52.5 million. Management stated cash, working capital, revolving availability and expected product-sale cash flows should fund operations, capital expenditures and debt service for at least 12 months beyond the filing date.
Outlook, risks and notable items
- No specific revenue, earnings or margin guidance was provided. Management expects SG&A and R&D investment to continue as it pursues sales growth, product development and regulatory approvals.
- Dermagraft manufacturing was suspended in Q4 2021 and sales in Q2 2022. The company plans to move manufacturing to a new facility or use a third-party manufacturer, anticipating long-term cost savings. It expects Apligraf substitution to limit revenue impact, but notes customer substitution or cost-savings shortfalls could hurt results.
- On February 3, 2023, the company announced a workforce reduction of 71 employees, about 7% of staff. Q1 restructuring charges were $1.9 million; $1.1 million of restructuring liabilities remained at quarter-end.
- Management reported a continuing material weakness in internal controls over financial reporting, involving identification and assessment of significant non-routine transactions, IT general controls and segregation of duties. Disclosure controls and internal control over financial reporting were deemed ineffective at March 31. ERP implementation was delayed, with go-live anticipated in 2023; remediation was not yet complete.
- A securities class action alleges misleading statements concerning revenue, sales growth and competition involving Affinity and PuraPly XT. The company moved to dismiss and intends to contest the case; outcome and damages are uncertain. Management accrued $0.2 million for certain pending lawsuits and said it did not expect material effects from outstanding legal matters based on its current knowledge.
- The filing identifies economic and financial-market uncertainty, including banking-sector turmoil, as risks to sales, suppliers, financing and operations. The company said it did not believe it had loss exposure from SVB’s receivership, but noted broader effects were uncertain. COVID-19 had not materially adversely affected results through quarter-end, though future effects were uncertain.
Investor facts to verify
- Whether revenue growth and improved gross margin persist, particularly given Surgical & Sports Medicine weakness and product-mix dependence.
- Whether operating cash flow recovers after the $5.1 million outflow, including management of receivables, inventory and prepaid expenses.
- Progress, cost and timing of Dermagraft manufacturing transition, and whether customers substitute Apligraf as expected.
- Remediation and independent testing of the material weakness, including ERP implementation and effective controls over significant transactions.
- Developments in the securities class action and any changes to the company’s assessment of legal exposure.